We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Feb 2018
  • Code : CMI1284
  • Industry : Pharmaceutical
  • Pages : 194
  • Formats :

Pet Cancer Therapeutics Market – Efficient Cancer Cure in Companion Animals

Pet cancer therapeutics are the novel drug molecules that exhibit high potential to reduce the effects of cancer, giving access to comprehensive cancer care with minimum side effects. Cancer therapies aims to permanently eradicate the cancerous cells prevalent in pets. The veterinarian recommends specific treatment program such as targeted therapy and combination therapy or chemotherapy depending on the type of cancer, stage, and nature of the cancer. The ongoing research activities undertaken by the scientists for the development of novel formulations and therapies is expected to accelerate the market growth. For instance, the scientists at University of Veterinary Medicine are currently exploring the molecular basis of cancer progression in canine cell lines, stating that the modern cancer therapy can be revolutionized with the introduction of targeted therapies.

The global pet cancer therapeutics market was valued at US$ 183.3 million in 2017 and is expected to witness a robust CAGR of 7.7% over the forecast period (2017 - 2025).

Figure 1. Global Pet Cancer Therapeutics Market (US$ Mn), by Region, 2017

pet cancer therapeutics market

Source: Coherent Market Insights (2018)

Increasing R&D initiatives for cancer management to augment market growth

Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatment is expected to be a major factor driving growth of the global pet cancer therapeutics market in near future. For instance, in 2017, Animal Cancer Foundation (ACF) received a US$ 1 million grant from the Blue Buffalo Foundation to support comparative oncology research, which aimed to study similarities between naturally occurring cancers in people and pets and find effective treatment in both species. Also, in 2016, the Petco Foundation and Blue Buffalo Foundation invested US$ 2.35 million to support pet cancer research and treatment, as it represents a major cause of illness and premature death in affected species worldwide. Moreover, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to create a biobank of dog tumors for providing insights on cancer cure through research, in order to develop the most effective cancer therapy. Furthermore, organizations such as Animal Cancer Foundation, Petco Foundation, Veterinary Cancer Society, and PetCure Oncology are conducting oncology research such as canine cancer genome project to understand the genetic makeup of cancer tumors in animals, in order to discover targeted drug therapies with least toxic doses. However, increasing adoption of alternative treatment methods such as herbal medications, homeopathy and adverse effects such as diarrhea, musculoskeletal disorder, anorexia and high cost associated with pet cancer treatment are the factors restraining the market growth.

Increasing incidence and remission rates of pet cancers to accelerate the market growth

Increasing prevalence of cancer indicates a need to adopt approved novel therapies, which are proved to be highly effective for the treatment of cancers in pets, thus, augmenting the pet cancer therapeutics market growth during the forecast period. According to the study by Fetch a Cure, 2015, dogs and cats have a higher incidence of tumors than humans, where dogs are 35 times more likely to develop skin cancer, 4 times more likely to develop breast tumors, and 8 times more likely to develop bone cancer. According to the study published by Animal Cancer Foundation, 2017, approximately around 25% of all dogs will develop a tumor at some point in their life. Furthermore, increasing number of relapsed cancer rates and the availability of relapsed/ refractory therapeutics integrated with veterinarian recommendation is expected to additionally generate the revenue for the market players. According to the study by petMD, LLC, 2015, about 95% of dogs treated for lymphoma with chemotherapy protocols and conventional treatments are expected to experience disease relapse or remission. The duration of remission is less than 15 months in 50% of dog species. In 2017, a novel chemotherapy drug named Tanovea-CA1 (rabacfosadine for injection), manufactured by VedDC, Inc. was conditionally approved by the FDA as a first line treatment for dogs to treat relapsed/refractory lymphoma and canine lymphoma. The conditional approval of drug allows manufacturer to legally sell Tanovea-CA1, before proving it meets the substantial evidence standard of effectiveness for full approval.

The major players operating the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.

The pet cancer therapeutics include chemotherapy drugs, targeted therapies, combination therapies, and immunotherapy vaccines, which are commonly recommended by the veterinary doctors. The drugs are mostly recommended to treat various conditions such as lymphoma, mast cell tumors, fibrosarcoma, hemangiosarcoma, and others. Currently, a wide range of formulations are available in the global market for the treatment of pet cancers, which can be administered in the form of tablets, injections or can be applied topically. Thus, the large variety of treatment options has made it easy for the pets to receive effective cancer treatment suitable to curb the condition.

Market Dynamics

The major factor driving growth of the pet cancer therapeutics market include robust number of pipeline drugs for the treatment of highly prevalent conditions such as lymphoma and melanoma. For instance, in 2017, Aratana Therapeutics received approval from the United States Department of Agriculture (USDA) Center for Veterinary Biologics for canine osteosarcoma vaccine- AT-014 for the treatment of dogs diagnosed with osteosarcoma, one year of age or older. The drug candidate was licensed exclusively from Advaxis, Inc. and is currently in the pivotal trial. Moreover, the private and government organizations such as Veterinary Cancer Society, Petco Foundation, and Animal Cancer Foundation are working together to formulate novel drugs for dogs and cats, which is a major factor expected to propel growth of the pet cancer therapeutics market over the forecast period. However, lack of awareness regarding pet diseases, high cost, and adverse effects of the drugs are the factors restraining pet cancer therapeutics market growth.

Key features of the study:

  • This report provides in-depth analysis of pet cancer therapeutics market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2017 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by the leading players
  • It profiles leading players in the global pet cancer therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Aratana Therapeutics, Inc., AB Science, Boehringer Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Rhizen Pharmaceuticals SA, Regeneus Ltd., Oasmia Pharmaceuticals AB, and Zoetis
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global pet cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pet cancer therapeutics market

Detailed Segmentation:

  • Global Pet Cancer Therapeutics Market, By Therapy Type:
    • Chemotherapy
    • Targeted Therapy
    • Combination Therapy
    • Immunotherapy
  • Global Pet Cancer Therapeutics Market, By Pet Type:
    • Cat
    • Dog
    • Horse
  • Global Pet Cancer Therapeutics Market, By Mode of Administration:
    • Oral
    • Intravenous
    • Topical
  • Global Pet Cancer Therapeutics Market, By Application:
    • Lymphoma
    • Mast Cell Cancer
    • Melanoma
    • Mammary and Squamous Cell Cancer
    • Others
  • Global Pet Cancer Therapeutics Market, By Geography:
    • North America
      • By Therapy Type:
        • Chemotherapy
        • Targeted Therapy
        • Combination Therapy
        • Immunotherapy
      • By Pet Type:
        • Cat
        • Dog
        • Horse
      • By Mode of Administration:
        • Oral
        • Intravenous
        • Topical
      • By Application:
        • Lymphoma
        • Mast Cell Cancer
        • Melanoma
        • Mammary and Squamous Cell Cancer
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Therapy Type:
        • Chemotherapy
        • Targeted Therapy
        • Combination Therapy
        • Immunotherapy
      • By Pet Type:
        • Cat
        • Dog
        • Horse
      • By Mode of Administration:
        • Oral
        • Intravenous
        • Topical
      • By Application:
        • Lymphoma
        • Mast Cell Cancer
        • Melanoma
        • Mammary and Squamous Cell Cancer
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Therapy Type:
        • Chemotherapy
        • Targeted Therapy
        • Combination Therapy
        • Immunotherapy
      • By Pet Type:
        • Cat
        • Dog
        • Horse
      • By Mode of Administration:
        • Oral
        • Intravenous
        • Topical
      • By Application:
        • Lymphoma
        • Mast Cell Cancer
        • Melanoma
        • Mammary and Squamous Cell Cancer
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Therapy Type:
        • Chemotherapy
        • Targeted Therapy
        • Combination Therapy
        • Immunotherapy
      • By Pet Type:
        • Cat
        • Dog
        • Horse
      • By Mode of Administration:
        • Oral
        • Intravenous
        • Topical
      • By Application:
        • Lymphoma
        • Mast Cell Cancer
        • Melanoma
        • Mammary and Squamous Cell Cancer
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Therapy Type:
        • Chemotherapy
        • Targeted Therapy
        • Combination Therapy
        • Immunotherapy
      • By Pet Type:
        • Cat
        • Dog
        • Horse
      • By Mode of Administration:
        • Oral
        • Intravenous
        • Topical
      • By Application:
        • Lymphoma
        • Mast Cell Cancer
        • Melanoma
        • Mammary and Squamous Cell Cancer
        • Others
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Therapy Type:
        • Chemotherapy
        • Targeted Therapy
        • Combination Therapy
        • Immunotherapy
      • By Pet Type:
        • Cat
        • Dog
        • Horse
      • By Mode of Administration:
        • Oral
        • Intravenous
        • Topical
      • By Application:
        • Lymphoma
        • Mast Cell Cancer
        • Melanoma
        • Mammary and Squamous Cell Cancer
        • Others
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Aratana Therapeutics, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • AB Science
    • Boehringer Ingelheim International GmbH
    • Zenoaq
    • Morphogenesis, Inc.
    • VetDC, Inc.
    • Karyopharm Therapeutics, Inc.
    • Rhizen Pharmaceutical SA
    • Regeneus Ltd.
    • Oasmia Pharmaceuticals AB
    • Zoetis

 “*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global pet cancer therapeutics market is estimated to surpass US$ 332.6 Million by 2025.
Major players operating in the global pet cancer therapeutics market include Aratana Therapeutics, Inc., AB Science, Boehinger Ingelheim International GmbH, Zenoaq, Morphogenesis, Inc., VetDC, Inc., Karyopharm Therapeutics, Inc., Regeneus Ltd., Rhizen Pharmaceuticals SA, Oasmia Pharmaceuticals AB, and Zoetis.
Increasing adoption of alternative treatment methods such as herbal medications, homeopathyand high cost associated with pet cancer treatment are some of the major factors that are expected to hamper growth of the market over the forecast period.
Increasing number of research grants to launch various anti-cancer therapies for veterinary cancer treatmentis one of the major factors that is expected to propel growth of the market over the forecast period.
The global pet cancer therapeutics market is estimated to exhibit a CAGR of 7.7% over the forecast period
Among therapy type, chemotherapy segment holds a dominant position in the pet cancer therapeutics market, owing to easy availability of the drugs and high recommendation by the veterinary doctors for opting chemotherapy.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo